Following Fifth NCE Delay, Amarin (AMRN) Has to Go-It-Alone on Vascepa - MKM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amarin (AMRN) Slips as FDA Updates Orange Book
December 14, 2012 2:28 PM ESTAmarin Corp Plc (NASDAQ: AMRN) shares slump in afternoon trading Friday following the FDA updating its Orange Book.
To access the Vascepa page at the FDA, click here.
Shares are down 0.7 percent today.... More
Amarin (AMRN) in Focus as Traders Await NCE Decision on Vascepa
December 14, 2012 1:07 PM ESTAmarin (Nasdaq: AMRN) shares are higher on the session as traders anticipate an NCE decision on Vascepa sometime today, though nothing is in stone.
Shares are 24 percent lower from the close on December 6th, with Amarin... More
